fda enforcement actions bpc-157 Legal Status: Regulations and Compounding fda warning letter bpc-157 unapproved
Description
the only meaningful adverse event documented in research literature is mild scalp tingling in the first few applications, which resolves quickly
Handling: Follow standard laboratory safety protocols
Brain 144 , 16321645 (2021)
Research demonstrates decreased prostaglandin levels, modified cytokine expression, and reduced edema at injury sites
